[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University College London Hospitals\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":156},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,44,71,92,114,134],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100608810","feasibility-trial-of-scarwork-for-post-breast-surgery-pain-syndrome-100608810",false,"NCT07206394","Feasibility Trial of ScarWork for Post-breast Surgery Pain Syndrome.","A Feasibility Trial of ScarWork on Post-breast Surgery Pain Syndrome (PBSPS) in Early Stage Breast Cancer Patients.","Inclusion Criteria:\n\n* Over the age of 18\n* Early breast cancer patients who have had breast surgery with curative intent\n* Radiotherapy completed ≥ 6 months previously\n* In remission with no sign of active local disease\n* Registering a score of ≥3 on perceived pain intensity or pain burden on a 10-point numerical rating scale (NRS)\n* English speaking and able to communicate reasonably well\n* Able to give informed consent\n* Willing to attend for regular treatment at RLHIM\n\nExclusion Criteria:\n\n* History of post-breast surgery wound complications\n* History of breast surgery unrelated to breast cancer treatment\n* History of previous ScarWork therapy\n* Diagnosis of lymphoedema\n* Severe co-morbidities or cognitive disability\n* Receiving physiotherapy for post-breast surgery pain syndrome at the time of trial","ALL","18 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"NA","Breast cancer is the most common cancer in women in the United Kingdom (UK). Most women are treated with a combination of surgery and radiotherapy. While these treatments are effective, they can cause ongoing breast pain for some, which can last months or even years. This long-term pain can have a major impact on quality of life, yet it is often overlooked and not well managed in routine care.\n\nOne in three women may still experience breast pain three years after treatment. The pain can come from scarring, tissue damage, or nerve changes caused by surgery and radiotherapy. Treatments for this pain are limited. Many patients are advised the pain will subside on its own or are given basic painkillers, which sometimes have limited impact.\n\nScarWork is a light-touch manual therapy, developed in the United States and aims to improve the way scars feel and look, reduce pain and tightness, and support healing. Although it has been available in the United Kingdom since 2014, there is very little research into whether ScarWork helps people who experience pain after breast cancer treatment.\n\nThis small study is a first step to see whether ScarWork could be a useful treatment for people who have experience breast pain after surgery and\u002For radiotherapy. The researchers want to know:\n\n* Can this therapy be delivered in an NHS setting?\n* Do people find it helpful?\n* Is it worth doing a larger trial in the future?\n\nParticipants will be randomly placed in one of two groups: one group will continue with usual care, and the other will receive up to five sessions of ScarWork in addition to usual care. Everyone in the study will be asked to complete short questionnaires about their pain and other symptoms, before and after treatment, and again one month later. Participants will also be invited to talk about their experiences in a short phone or online interview.\n\nThis research will help show whether ScarWork might be a useful option for people dealing with breast pain after treatment. It will also help researchers design a larger trial in the future to test ScarWork more fully.",[26],"Breast Cancer Early Stage Breast Cancer (Stage 1-3)",[28,29,30],"breast cancer","ScarWork","feasibility study","RECRUITING","2025-09-25",{"date":34,"type":35},"2025-10-03","ACTUAL",{"date":37,"type":35},"2025-06-20",{"date":39,"type":20},"2026-06-30",{"name":41,"class":42},"University College London Hospitals","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":43},"100584935","somatic-tracking-for-tinnitus-100584935","NCT06895824","Somatic Tracking for Tinnitus","Can Somatic Tracking Help People Living with Tinnitus?","Inclusion Criteria:\n\n* Experiencing distressing tinnitus\n* Sufficient English language and hearing ability to take part\n* Completed all relevant medical and audiological investigations and concluded ensuing treatment for any underlying disease\n* Not be engaging in any other therapy for tinnitus.\n\nExclusion Criteria:\n\n* Risk to self (scoring 'nearly every day' on PHQ-9 question \"Thoughts that you would be better off dead, or of hurting yourself in some way?\")\n* Severe mental health difficulties (PHQ-9 score of 20 or more)",{"count":52,"type":20},100,[23],"We are examining the effect of mindfulness meditation on attitudes towards tinnitus, as well as physical and psychological distress associated with the condition. The meditation is designed to promote neuroplasticity, fostering new neural connections to help you reinterpret tinnitus through a lens of safety and reduce the perception of threat. This approach integrates several techniques from various psychological therapies which have been promising in reducing tinnitusrelated distress. Therefore, the purpose of this study is to see whether a guided mindfulness meditation intervention is effective in improving the acceptance of tinnitus symptoms, as well as reducing tinnitus-related distress in people living with tinnitus.",[56],"Tinnitus",[58,59,60,61,62],"tinnitus","mindfulness","mindfulness meditation","somatic tracking","tinnitus distress","2025-03-19",{"date":65,"type":35},"2025-03-26",{"date":67,"type":35},"2024-12-11",{"date":69,"type":20},"2025-05",{"name":41,"class":42},{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":43},"100560307","an-observational-study-of-predictors-and-outcomes-of-lung-cancer-in-never-smokers-in-the-uk-100560307","NCT06575439","An Observational Study of Predictors and Outcomes of Lung Cancer in Never-smokers in the UK","OLIVE","Inclusion Criteria:\n\n* All adult participants from age of 18 who are diagnosed or treated with primary lung cancer through radiology or histology at any participating study site\n\nExclusion Criteria:\n\n* Participants who have ever smoked cigarettes or tobacco will be excluded; this is defined as:\n\n  * More than 100 cigarettes or 75g tobacco in their lifetime\n  * Those who have received a prescription for nicotine replacement therapy\n* For prospective participants, those who cannot consent will be excluded",{"count":79,"type":20},225,"OBSERVATIONAL","The goal of this observational study is to improve the early detection of lung cancer in adults who have smoked less than 100 tobacco cigarettes (\"never-smokers\") in the United Kingdom. The main questions it aims to answer are:\n\n* To describe characteristics such as demographics, co-morbidities and environmental exposures\n* To describe participant pathways including presentation mode and symptoms to understand if earlier diagnosis would be possible\n* To describe participant outcomes such as cancer stage, treatment and mortality\n* To quantitatively or qualitatively measure modifiable and non-modifiable factors that may be associated with LCINS including environmental measures, blood tests and genomic data.\n\nParticipants will currently have no change to their usual care.",[83],"Lung Cancer","2024-12-08",{"date":86,"type":35},"2024-12-12",{"date":88,"type":35},"2024-09-17",{"date":90,"type":20},"2029-09",{"name":41,"class":42},{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":113},"100494976","volatile-non-invasive-biomarkers-of-epileptic-seizures-100494976","NCT05725174","Volatile Non-Invasive Biomarkers of Epileptic Seizures","VIBES","Inclusion Criteria:\n\n1. Patients who have been admitted to either University College London's Queen's Square EEG-telemetry unit or Chalfont Centre for Epilepsy, for diagnosis of seizure events.\n2. Patients aged 18 years or above\n\nExclusion Criteria:\n\n1. Patients with active infection or who have taken antibiotics within 4 weeks\n2. Patients on immunosuppressive medications\n3. Patients with co-morbidities preventing breath collection\n4. Patients unable to provide informed consent.",{"count":100,"type":20},270,"Breath and sweat samples will be collected from people who have been admitted to hospital after a potential seizure and analysed by the team. The researchers then hope to identify a pattern of small molecules that can distinguish seizures from other events, and perhaps determine the severity of the seizure.",[103,104],"Epilepsy","Non-Epileptic Seizure","2024-12-03",{"date":107,"type":35},"2024-12-06",{"date":109,"type":35},"2023-01-30",{"date":111,"type":20},"2026-11-01",{"name":41,"class":42},2,{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":120,"targetDuration":122,"studyType":80,"phases":4,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":43},"100413244","study-of-late-foetal-human-organ-development-100413244","NCT04661059","Study of Late-foetal Human Organ Development","Inclusion Criteria:\n\n* ≥18 years old pregnant women who attend the Fetal Medicine Unit for concerns about a fetal abnormality where they decide to proceed to termination of pregnancy\n\nExclusion Criteria:\n\n* Screening labs positive for maternal HIV, Hepatitis B and Hepatitis C, Chlamydia and Herpes.\n* Subject unable to make an informed decision about termination of pregnancy.",{"count":121,"type":20},2000,"20 Years","Knowledge about abnormal organ development is important to understand pathology and to develop novel treatment approaches for individuals with congenital and acquired disease. Most of our current understanding is based on examination of tissues from the embryo and early fetus, collected from women undergoing termination of pregnancy in the first trimester (third) of pregnancy. There is very little known about normal and abnormal organ development from a developmental perspective during the crucial last two-thirds of pregnancy when much remodelling of fetal tissues occurs. We aim to collect tissue from a variety of developing fetal organs in the last two-thirds of pregnancy from women who decide to undergo a termination of pregnancy and who wish to undergo a clinical fetal postmortem (PM) examination.",[125],"Congenital Disorders","2023-12-04",{"date":128,"type":35},"2023-12-05",{"date":130,"type":35},"2022-02-03",{"date":132,"type":20},"2040-12-31",{"name":41,"class":42},{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":142,"enrollmentInfo":143,"targetDuration":122,"studyType":80,"phases":4,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":43},"100527687","pd-frontline-part-of-rapsodi-gd-remote-assessment-of-people-with-parkinsons-100527687","NCT06151002","PD Frontline (Part of RAPSODI GD) Remote Assessment of People With Parkinson's","PD Frontline, Part of RAPSODI GD (Remote Assessment of Parkinsonism Supporting Ongoing Development of Interventions in Gaucher's Disease) to Build an Online Trial-ready Cohort of GBA Genotyped People With Parkinson's","PD Frontline","Inclusion Criteria:\n\n* Formal diagnosis of Parkinson Disease\n\nExclusion Criteria:\n\n* Confirmation that the individual carries a GBA variant (GBA positive). These individuals will be referred to sister-study, RAPSODI.\n* History of Parkinsonism (progressive supranuclear palsy, multiple system atrophy, traumatic, manganese toxicity, postencephalitic, vascular PD; drug induced PD; corticobasal degeneration)\n* Individuals with another neurological disorder including: dementia, movement disorders, and motor neurone disease.\n* Individuals on drugs known to be associated with parkinsonism, including neuroleptic agents (Amisulpride, Chlorpromazine Hydrochloride, Flupenthixol, Fluphenazine Hydrochloride, Haloperidol, Methotrimeprazine, Levomepromazine, Olanzapine, Oxypertine, Pericyazine, Perphenazine, Pimozide, Pipotiazine, Prochlorperazine, Promazine Hydrochloride, Reserpine, Risperidone, Sulpiride, Thioridazine, Trifluoperazine, Zuclopenthixol acetate, Zotepine), plus Bupropion, , Lithium, Methyldopa, Metoclopramide and Sodium Valproate).","90 Years",{"count":144,"type":20},4800,"PD Frontline (part of RAPSODI GD) is an online study observational study with the goal of bringing People with Parkinson's to the frontline of research by getting them trial ready. To do this, participants are offered genetic sequencing for the GBA and LRRK2 gene with an at-home saliva collection kit.",[147],"Parkinson Disease","2023-11-28",{"date":150,"type":35},"2023-11-30",{"date":152,"type":35},"2020-02-15",{"date":154,"type":20},"2040-08-20",{"name":41,"class":42},""]